PlantForm Corporation

PlantForm Corporation is a privately-held Canadian biopharmaceutical company that specializes in the development and production of antibody and protein drugs through its proprietary vivoXPRESS platform. This plant-based manufacturing system utilizes genetically modified plants grown in contained greenhouse environments to produce biopharmaceuticals. By employing a unique molecular cloning process and transient expression system, the platform achieves high drug expression levels with mammalian-type glycosylation, effectively mitigating risks of immunogenicity. The technology offers distinct advantages over traditional mammalian and bacterial cell culture systems, including faster development timelines—sometimes as short as six weeks—unlimited scale-up capabilities, and significantly reduced manufacturing costs, which are estimated to be as much as 90 percent lower than conventional methods.

The company leverages this technology to advance a diverse pipeline that includes both innovator drugs and biosimilar versions of major therapeutics, such as those targeting cancer and age-related macular degeneration. Beyond commercial biologics, PlantForm addresses public health and safety by developing medical countermeasures for terrorism threats, such as antidotes for ricin and nerve agents. Supported by intellectual property, including several issued patents, the company provides Contract Development and Manufacturing Organization (CDMO) services, making its platform available to partners for the production of complex proteins. Their efforts are bolstered by collaborations with organizations such as the Ministry of Health in Brazil, Defence Research and Development Canada, and the Bill & Melinda Gates Foundation, aiming to improve patient access to high-value medications.